Eclat Pharmaceuticals announced that it has ended shortages of Bloxiverz (neostigmine methylsulfate) injection for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.
Bloxiverz is a cholinesterase inhibitor that works by reducing the breakdown of acetylcholine. Neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Bloxiverz is the only FDA approved neostigmine methylsufate injection currently available. The FDA is working on removing all FDA unapproved neostigmine methylsulfate injections.
Bloxiverz is available in 0.5mg/mL and 1mg/mL strengths in 10mL multi-dose vials.
For more information call (636) 449-1830 or visit Bloxiverz.com.